Vanquish
Acetaminophen, Aspirin, And Caffeine
Dse Healthcare Solutions, Llc
Human Otc Drug
NDC 42364-0011Vanquish also known as Acetaminophen, Aspirin, And Caffeine is a human otc drug labeled by 'Dse Healthcare Solutions, Llc'. National Drug Code (NDC) number for Vanquish is 42364-0011. This drug is available in dosage form of Tablet, Coated. The names of the active, medicinal ingredients in Vanquish drug includes Acetaminophen - 194 mg/1 Aspirin - 227 mg/1 Caffeine - 33 mg/1 . The currest status of Vanquish drug is Active.
Drug Information:
| Drug NDC: | 42364-0011 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Vanquish |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Acetaminophen, Aspirin, And Caffeine |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Dse Healthcare Solutions, Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Tablet, Coated |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | ACETAMINOPHEN - 194 mg/1
ASPIRIN - 227 mg/1
CAFFEINE - 33 mg/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 15 Jul, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 16 Jan, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part343 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | DSE Healthcare Solutions, LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 243694
1101754
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| NUI: | N0000000160
N0000008836
M0001335
N0000175722
N0000175578
N0000008832
N0000175739
N0000175729
N0000175790
M0023046
|
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). |
| UNII: | 362O9ITL9D
R16CO5Y76E
3G6A5W338E
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class MOA: | Cyclooxygenase Inhibitors [MoA]
|
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. |
| Pharmacologic Class EPC: | Nonsteroidal Anti-inflammatory Drug [EPC]
Platelet Aggregation Inhibitor [EPC]
Central Nervous System Stimulant [EPC]
Methylxanthine [EPC]
|
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. |
| Pharmacologic Class PE: | Decreased Prostaglandin Production [PE]
Decreased Platelet Aggregation [PE]
Central Nervous System Stimulation [PE]
|
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. |
| Pharmacologic Class CS: | Anti-Inflammatory Agents, Non-Steroidal [CS]
Xanthines [CS]
|
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. |
| Pharmacologic Class: | Anti-Inflammatory Agents
Non-Steroidal [CS]
Central Nervous System Stimulant [EPC]
Central Nervous System Stimulation [PE]
Cyclooxygenase Inhibitors [MoA]
Decreased Platelet Aggregation [PE]
Decreased Prostaglandin Production [PE]
Methylxanthine [EPC]
Nonsteroidal Anti-inflammatory Drug [EPC]
Platelet Aggregation Inhibitor [EPC]
Xanthines [CS]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 42364-0011-1 | 1 BOTTLE in 1 CARTON (42364-0011-1) / 100 TABLET, COATED in 1 BOTTLE | 15 Jul, 2018 | N/A | No |
| 42364-0011-2 | 1 BOTTLE in 1 CARTON (42364-0011-2) / 120 TABLET, COATED in 1 BOTTLE | 15 Jul, 2018 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Active ingredients (in each caplet) purpose acetaminophen 194 mg pain reliever aspirin 227 mg (nsaid) nonsteroidal anti-inflammatory drug pain reliever caffeine 33 mg pain reliever aid
Product Elements:
Vanquish acetaminophen, aspirin, and caffeine acetaminophen acetaminophen aspirin aspirin caffeine caffeine cellulose, microcrystalline hypromelloses maltodextrin medium-chain triglycerides polydextrose povidone k30 silicon dioxide sodium starch glycolate type a corn starch, corn stearic acid talc titanium dioxide vanquish vanquish 100s label vanquish 120s label vanquish 120s carton vanquish 100s carton
Indications and Usage:
Uses temporarily relieves minor pain due to headache arthritis backache colds menstrual cramps muscle aches
Warnings:
Warnings reye's syndrome: children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. when using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of reye's syndrome, a rare but serious illness. aspirin may cause a severe allergic reaction which may include: hives facial swelling asthma (wheezing) shock allergy alert: acetaminophen may cause severe skin reactions. symptoms may include: skin reddening blisters rash if a skin reaction occurs, stop use and seek medical help right away. liver warning: this product contains acetaminophen. severe liver damage may occur if you take more than 8 caplets in 24 hours, which is the maximum daily amount for this product with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product stomach bleeding warning: this product contains an nsaid, which may cause severe stomach bl
Read more...eeding. the chance is higher if you are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription nsaids (aspirin, ibuprofen, naproxen, or others) have 3 or more alcoholic drinks every day while using this product take more or for a longer time than directed caffeine warning: the recommended dose of this product contains about as much caffeine as a cup of coffee. limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heartbeat.
Do Not Use:
Warnings reye's syndrome: children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. when using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of reye's syndrome, a rare but serious illness. aspirin may cause a severe allergic reaction which may include: hives facial swelling asthma (wheezing) shock allergy alert: acetaminophen may cause severe skin reactions. symptoms may include: skin reddening blisters rash if a skin reaction occurs, stop use and seek medical help right away. liver warning: this product contains acetaminophen. severe liver damage may occur if you take more than 8 caplets in 24 hours, which is the maximum daily amount for this product with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product stomach bleeding warning: this product contains an nsaid, which may cause severe stomach bleeding. the chance is higher if you are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription nsaids (aspirin, ibuprofen, naproxen, or others) have 3 or more alcoholic drinks every day while using this product take more or for a longer time than directed caffeine warning: the recommended dose of this product contains about as much caffeine as a cup of coffee. limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heartbeat.
Dosage and Administration:
Directions do not take more than the recommended dose drink a full glass of water with each dose adults and children 12 years and over: take 2 caplets every 6 hours, not to exceed 8 caplets in 24 hours unless directed by a doctor children under 12 years: consult a doctor
Stop Use:
Stop use and ask a doctor if an allergic reaction occurs. seek medical help right away. you experience any of the following signs of stomach bleeding: feel faint vomit blood have bloody or black stools have stomach pain that does not get better pain gets worse or lasts more than 10 days redness or swelling is present ringing in the ears or loss of hearing occurs new symptoms occur
Package Label Principal Display Panel:
Principal display panel new look! same trusted formula made in usa with domestic and imported ingredients effective headache relief vanquish ® aspirin (nsaid) / acetaminophen / caffeine pain reliever / pain reliever aid 100 analgesic coated caplets r51019 011-2201 c 02/22 top panel do not use this product if printed safety seal under cap is torn or missing. effective headache relief vanquish ® 50 years of proven pain relief refreshed for today's digital lifestyle expires bottom panel questions or comments? call: 1-800-214-2379 vanquish ® is a registered trademark of dse healthcare solutions distributed by dse healthcare solutions, llc 27070 miles rd, suite a, solon oh 44139 made in usa effective headache relief vanquish ® aspirin (nsaid) / acetaminophen / caffeine pain reliever / pain reliever aid 100 analgesic coated caplets vanquish ® is a registered trademark of svads holdings sa distributed by dse healthcare solutions, llc 27070 miles rd, suite a, solon oh 44139 www.vanquishheadacherelief.com expires 11043-03-17 011-2201 c made in usa do not use this product if printed safety seal under cap is torn or missing. effective headache relief vanquish ® aspirin (nsaid) / acetaminophen / caffeine pain reliever / pain reliever aid 120 analgesic coated caplets distributed by dse healthcare solutions, llc 27070 miles rd, suite a, solon oh 44139 011-2202 l expires 82-375210 11044-03-17 made in usa - bonus - 20% more! effective headache relief vanquish ® aspirin (nsaid) / acetaminophen / caffeine pain reliever / pain reliever aid 120 analgesic coated caplets vanquish ® is a registered trademark of svads holdings sa distributed by dse healthcare solutions, llc 27070 miles rd, suite a, solon oh 44139 www.vanquishheadacherelief.com expires 11045-03-17 011-2202 c
Further Questions:
Questions or comments? call: 1-800- 214-2379 www.vanquishheadacherelief.com vanquish ® is a registered trademark of dse healthcare solutions distributed by dse healthcare solutions, llc 27070 miles rd, suite a, solon, oh 44139